Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $150 to $155.
Barclays Maintains Overweight on Cirrus Logic, Raises Price Target to $95
Barclays analyst Blayne Curtis maintains Cirrus Logic (NASDAQ:CRUS) with a Overweight and raises the price target from $85 to $95.
